|Bid||28.76 x 2900|
|Ask||28.77 x 4000|
|Day's Range||28.59 - 28.97|
|52 Week Range||28.30 - 54.93|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||15.73|
|Earnings Date||Jan 29, 2024 - Feb 02, 2024|
|Forward Dividend & Yield||1.64 (5.70%)|
|Ex-Dividend Date||Nov 09, 2023|
|1y Target Est||40.00|
Subscribe to Yahoo Finance Plus to view Fair Value for PFE
NEW YORK, December 10, 2023--Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). The results from the BASIS trial demonstrated a statistically significant and clinically meaningful effect on annualized bleeding rate (ABR). The findings were presented today at t
Study results disclosed at the American Society of Hematology meeting Saturday suggested potential for cell therapy in lupus and pointed out drug trial limitations.
I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap. In today's video I will look at three dividend stocks trading at their 52-week lows and examine their metrics to determine if the stock is cheap or not.